RT Journal Article T1 Initial experience with golimumab in clinical practice for ulcerative colitis. A1 Castro-Laria, Luisa A1 Argüelles-Arias, Federico A1 García-Sánchez, Valle A1 Benítez, José Manuel A1 Fernández-Pérez, Ramón A1 Trapero-Fernández, Ana María A1 Gallardo-Sánchez, Francisco A1 Pallarés-Manrique, Héctor A1 Gómez-García, María A1 Cabello-Tapia, María José A1 Talavera-Fabuel, Aurora A1 Bejarano-García, Ana A1 Leo-Carnerero, Eduardo A1 Hernández-Martínez, Álvaro A1 Caunedo-Álvarez, Ángel A1 Herrerías-Gutiérrez, Juan Manuel AB Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice. Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg. Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%. In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe therapy, given that there were no adverse effects in the patients studied. SN 1130-0108 YR 2016 FD 2016 LK http://hdl.handle.net/10668/9747 UL http://hdl.handle.net/10668/9747 LA en DS RISalud RD Apr 6, 2025